melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our results reveal that MITF is a lineage-specific regulator of metabolic reprogramming, whereby fatty acid composition is a driver of melanoma phenotype switching, and highlight that cell phenotype dictates the response to drugs targeting lipid metabolism.
|
31733993 |
2020 |
melanoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The role of microphthalmia-associated transcription factor (MITF) in the upregulation of MC1R was also examined in A2058 and MEWO cells.
|
31318566 |
2019 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our results reveal a previously unsuspected role for MITF in metabolism and the network of factors underpinning the hypoxic response in melanoma.
|
31207090 |
2019 |
melanoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
GLI2, a transcription factor that acts downstream of Hedgehog signaling, is also a direct transcriptional target of the TGF-β/SMAD pathway that contributes to melanoma progression and exerts transcriptional antagonistic activities against MITF.
|
31208857 |
2019 |
melanoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Melanoma plasticity promotes a switch between proliferative and invasive phenotypes characterized by different transcriptional programs of which MITF is a critical regulator.
|
30254208 |
2019 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Cycloartane triterpenoid (23R, 24E)-23-acetoxymangiferonic acid inhibited proliferation and migration in B16-F10 melanoma via MITF downregulation caused by inhibition of both β-catenin and c-Raf-MEK1-ERK signaling axis.
|
30084054 |
2019 |
melanoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Here, we have investigated the effect of MITF on melanoma chemokine expression and immune cell attraction.
|
30502589 |
2019 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Single-cell RNA sequencing revealed MITF-independent residual disease was heterogeneous depending on melanoma subtype.
|
31582381 |
2019 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here we reveal a negative regulatory loop between Notch signaling and microphthalmia-associated transcription factor (MITF), the central regulator of melanoma progression and the driver of melanoma plasticity.
|
30699982 |
2019 |
melanoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
This melanogenic function of UVRAG is controlled by the melanocyte-specific transcription factor MITF as a downstream effector of the α-melanocyte-stimulating hormone (α-MSH)-cAMP signaling in the suntan response, which is compromised in BRAF mutant melanoma.
|
30209981 |
2019 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In addition, SUMOylation of MITF modulates renal tumors secondary to melanoma, Similarly, SUMOylation of tumor suppressor gene VHL regulates the occurrence of renal cell carcinoma in VHL syndrome.
|
30707172 |
2019 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We identified (likely) pathogenic variants in established melanoma susceptibility genes in 18 families (n = 3 BAP1, n = 15 MITF p.E318K; diagnostic yield 4.0%).
|
30414346 |
2019 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In the 25 yr since the gene encoding the microphthalmia-associated transcription factor (MITF) was first isolated, MITF has emerged as a key coordinator of many aspects of melanocyte and melanoma biology.
|
31123060 |
2019 |
melanoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
MITF level and expression of MITF-dependent pigmentation-related genes, <i>MLANA</i>, <i>PMEL</i>, <i>TYR,</i> and <i>DCT</i>, in drug-naïve and vemurafenib- or trametinib-treated patient-derived melanoma cell lines and their drug-resistant counterparts were analysed and referred to genomic alterations.
|
31354817 |
2019 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In addition, melanoma-specific network analysis followed by Kaplan-Meier analysis along with log-rank tests identified tyrosinase, hedgehog acyltransferase, BRCA1-associated protein 1 and melanocyte inducing transcription factor as potential therapeutic targets for melanoma.
|
31289481 |
2019 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Moreover, the analyzed drugs decrease/increase MITF amount depending on the type of melanoma.
|
31172223 |
2019 |
melanoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The dependence of TFIIH-CAK on sequence-specific MITF and c-MYC constitutes a previously unrecognized mechanism feeding into super-enhancer-driven or other oncogenic transcriptional circuitries, which supports the concept of a transcription-directed therapeutic intervention in melanoma.
|
30651597 |
2019 |
melanoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
SIGNIFICANCE: These results show that MITF is a major downstream target of p300 in human melanoma whose expression is predictive of melanoma response to small-molecule inhibition of p300 HAT activity.
|
30910803 |
2019 |
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A critical transcription factor for RPE development and function is the microphthalmia-associated transcription factor MITF and its germline mutations are associated with clinically distinct disorders, including albinism, microphthalmia, retinal degeneration, and increased risk of developing melanoma.
|
31242455 |
2019 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Conceptually, we focused on two different pivotal signalling pathways (mediated by microphthalmia-associated transcription factor (MITF) and IFNγ) to construct the evolving trajectories of melanoma and described each of the cell states.
|
30967646 |
2019 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF<sup>high</sup> /AXL<sup>low</sup> melanoma.
|
30277012 |
2019 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Loss of SR-BI Down-Regulates MITF and Suppresses Extracellular Vesicle Release in Human Melanoma.
|
30823658 |
2019 |
melanoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Understanding the normal and pathophysiological roles of MITF and related transcription factors may provide important clinical insights into melanoma therapy.
|
30705290 |
2019 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
However, MiTF immunoexpression has also been observed in histiocytes, macrophages, smooth muscle cells and fibroblasts, which raise the concern of fibrohistiocytic (FH) lesions being misdiagnosed as melanoma based on MiTF immunoreactivity.
|
29773427 |
2018 |
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We demonstrate that collagen stiffness induces melanoma differentiation through a YAP/PAX3/MITF axis and show that in melanoma patients increased collagen abundance correlates with nuclear YAP localization.
|
29545604 |
2018 |